Windtree grants Lee’s Asian rights to its KL4 surfactant products, including Aerosurf and Surfaxin

Windtree Therapeutics Inc. (OTCQB:WINT) granted Lee’s Pharmaceutical Holdings Ltd. (HKSE:950) exclusive rights to develop and commercialize KL4 surfactant products in China, Taiwan, Thailand and 13 other Asian territories based on Windtree’s KL4 surfactant and aerosolization technologies. The deal includes Aerosurf lucinactant, an aerosolized KL4 surfactant currently in an international Phase IIb trial to prevent respiratory distress syndrome (RDS) in premature infants; Surfaxin lucinactant, a humanized lung surfactant marketed in the U.S. for the same indication; and Surfaxin LS, a next-generation, lyophilized Surfaxin formulation. Windtree also granted Lee’s an exclusive license to manufacture KL4 surfactant for use in non-aerosol surfactant products in the designated territories...